2004 Issues

February 2004 Volume 11 Issue 1

Comparison of the Effectiveness of Various Deaeration Techniques Owen S. Degenhardt 1, Bonnie Waters 1,Anna Rebelo-Cameirao 1, Annelene Meyer 2,Heiko Brunner 2, and Nicholas P.Toltl 1 1. Eli Lilly Canada, Lilly Analytical Research Laboratories, Scarborough,Ontario, Canada 2. Lilly Research Laboratories, Lilly Forschung GmbH,Hamburg,Germany Developing a Discriminating Dissolution Procedure for a Dual Active Pharmaceutical Product with Unique Solubility Characteristics Lagace, M.,Gravelle, L., Di Maso, M. and McClintock, S. Department of Pharmaceutical Research and Development, Merck Frosst Canada & Co., Kirkland,Quebec, Canada Introduction to the Validation of a Dissolution Apparatus Sharon M.Averell Frost Wyeth Vaccines, Sanford,NC PhRMA Establishes Dissolution Expert Team Peter Scott QA Analytical Services, Method Services, AstraZeneca,Westborough, MA Question & Answer Section Margareth Marques and William Brown United States Pharmacopeia, Rockville,MD Meeting Report: Conference on Dissolution, Bioequivalence, and Bioavailability Tahseen Mirza 1 and Vivian Gray 2 1. Novartis Pharmaceuticals, East Hanover, NJ 2. V. A. Gray Consulting, Inc., Hockessin, DE

August 2004 Volume 11 Issue 3

The Future of Dissolution Testing: USP,Academic, FDA, and Industry Perspectives Dissolution: a Continuing Perspective Roger L.Williams, 1 and Thomas Foster, 2 1 Chair, Council of Experts 2 Chair, Biopharmaceutics Expert Committee United States Pharmacopeia, Rockville,MD Future Directions for Academic Researchin Dissolution Testing Jennifer B. Dressman J.W. Goethe University, Frankfurt am Main,Germany Role of Dissolution Testing: Regulatory Perspectives Vinod P. Shah Office of Pharmaceutical Science Center for Drug Evaluation and Research Food and Drug Administration, Rockville,MD Future Directions for Dissolution Testing in the Pharmaceutical Industry Vivian A. Gray Dissolution Technologies,Hockessin, DE The Development and Validation of a Dissolution Method for Clomipramine Solid Dosage Forms Mehdi Ansari 1,Maryam Kazemipour 2, and Javad Talebnia 1 1 Department of Pharmaceutics, Faculty of Pharmacy, Kerman Medical Sciences University, Kerman, Iran 2 Department of Chemistry, Faculty of Sciences, Kerman Azad University, Kerman, Iran Statistical Properties of the Dissolution Test of the USP Carlos D. Saccone 1, Julio Tessore 1, Silvino A. Olivera 2, and Nora S. Meneces 1 1 University of the Republic of Uruguay, Faculty of Engineering, Industrial Production Department, Montevideo,Uruguay 2 University of the Republic of Uruguay, Faculty of Chemistry, Estrella Campos Department, Montevideo,Uruguay Question & Answer Section Margareth Marques and William Brown United States Pharmacopeia, Rockville,MD

November 2004 Volume 11 Issue 4

Measurement of Dissolved Oxygen as a Determination of Media Equilibrium During Dissolution Testing Thomas Curley,Richard Forsyth, Susan Sun,Kyle Fliszar, Mitch Colletto and Gregory P.Martin Pharmaceutical Analysis & Control, PR&D, Merck & Co.,West Point, PA A New Crescent-shaped Spindle for Drug Dissolution Testing–But Why a New Spindle? Saeed A. Qureshi, Ph.D. Health Products and Food Branch, Health Canada,Ottawa, Canada A More Relevant Dissolution Method for Evaluation of a Floating Drug Delivery System Mukesh C.Gohel, Pavak R.Mehta, Rikita K. Dave and Nehal H. Bariya Department of Pharmaceutics and Pharmaceutical Technology, L. M.College of Pharmacy, Ahmedabad, India FIP/WHO/CHINA Bioequivalence and Hands-on- Dissolution Workshop Report Vinod P. Shah, Ph.D. FIP Scientific Secretary Controlled Release Society Annual Meeting Report: Dissolution Highlights Vivian Gray Dissolution Technologies, Hockessin, DE Question & Answer Section Margareth Marques and William Brown United States Pharmacopeia, Rockville,MD